Curated Information
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus® v6.5.9.3
Powered by Cell Signaling Technology
Home > Curated Information Page > PubMed Id: 18283331
Vojtechov√° M, et al. (2008) Regulation of mTORC1 signaling by Src kinase activity is Akt1-independent in RSV-transformed cells. Neoplasia 10, 99-107 18283331
This page summarizes selected information from the record referenced above and curated into PhosphoSitePlus®, a comprehensive online resource for the study of protein post-translational modifications (NAR, 2015, 43:D512-20). To learn more about the scope of PhosphoSitePlus®, click here.
Information from this record has been curated, but not yet edited in PhosphoSitePlus® and may be incomplete.
Click on the protein name to open the protein page, and on the RSD number to open the site page.
Download

T308-p - Akt1 (human)
Modsite: kDGAtMKtFCGtPEy SwissProt Entrez-Gene
Orthologous residues
Akt1 (human): T308‑p, Akt1 iso2 (human): T246‑p, Akt1 (mouse): T308‑p, Akt1 (rat): T308‑p, Akt1 (fruit fly): T423‑p, Akt1 (cow): T308‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Cellular systems studied:  cell lines
Species studied:  hamster
Comments:  RSV-transformed hamster fibroblasts H19, non transformed hamster fibroblasts NIL-2, NILA
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
DMSO increase
SU6656 DMSO inhibit treatment-induced increase
Akt1 (human) no change compared to control
4-HT Akt1 (human) increase
SU6656 4-HT no effect upon treatment-induced increase
DMSO increase
SU6656 DMSO inhibit treatment-induced increase
4-HT DMSO no effect upon treatment-induced increase
4-HT SU6656 augment treatment-induced decrease
Akt1 (human), Src (human) no change compared to control
tamoxifen Akt1 (human), Src (human) increase

Y326-p - Akt1 (human)
Modsite: EVLEDNDyGRAVDWW SwissProt Entrez-Gene
Orthologous residues
Akt1 (human): Y326‑p, Akt1 iso2 (human): Y264‑p, Akt1 (mouse): Y326‑p, Akt1 (rat): Y326‑p, Akt1 (fruit fly): Y441‑p, Akt1 (cow): Y326‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Cellular systems studied:  cell lines
Species studied:  hamster
Comments:  RSV-transformed hamster fibroblasts H19, non transformed hamster fibroblasts NIL-2, NILA
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
DMSO increase
SU6656 DMSO inhibit treatment-induced increase
Akt1 (human) no change compared to control
4-HT Akt1 (human) no change compared to control
SU6656 4-HT no change compared to control
DMSO increase
SU6656 DMSO inhibit treatment-induced increase
4-HT DMSO no effect upon treatment-induced increase
4-HT SU6656 augment treatment-induced decrease
Akt1 (human), Src (human) no change compared to control DN Src,iAkt
4-HT no change compared to control

S473-p - Akt1 (human)
Modsite: RPHFPQFsysAsGtA SwissProt Entrez-Gene
Orthologous residues
Akt1 (human): S473‑p, Akt1 iso2 (human): S411‑p, Akt1 (mouse): S473‑p, Akt1 (rat): S473‑p, Akt1 (fruit fly): S586‑p, Akt1 (cow): S473‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Cellular systems studied:  cell lines
Species studied:  hamster
Comments:  RSV-transformed hamster fibroblasts H19, non transformed hamster fibroblasts NIL-2, NILA
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
DMSO increase
SU6656 DMSO inhibit treatment-induced increase
Akt1 (human) no change compared to control
4-HT Akt1 (human) increase
SU6656 4-HT no effect upon treatment-induced increase
DMSO increase
SU6656 DMSO inhibit treatment-induced increase
4-HT DMSO no effect upon treatment-induced increase
4-HT SU6656 augment treatment-induced decrease
Akt1 (human), Src (human) no change compared to control
tamoxifen Akt1 (human), Src (human) increase

S2448-p - mTOR (human)
Modsite: RsRtRtDsysAGQsV SwissProt Entrez-Gene
Orthologous residues
mTOR (human): S2448‑p, mTOR (mouse): S2448‑p, mTOR (rat): S2448‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Cellular systems studied:  cell lines
Species studied:  hamster
Comments:  RSV-transformed hamster fibroblasts H19, non transformed hamster fibroblasts NIL-2, NILA
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
DMSO increase
SU6656 DMSO inhibit treatment-induced increase

S235-p - S6 (human)
Modsite: IAKRRRLssLRAsts SwissProt Entrez-Gene
Orthologous residues
S6 (human): S235‑p, S6 (mouse): S235‑p, S6 (rat): S235‑p, S6 (fruit fly): A234‑p, S6 (cow): S235‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Cellular systems studied:  cell lines
Species studied:  hamster
Comments:  RSV-transformed hamster fibroblasts H19, non transformed hamster fibroblasts NIL-2, NILA
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
DMSO increase
SU6656 DMSO inhibit treatment-induced increase
DMSO increase
SU6656 DMSO inhibit treatment-induced decrease
rapamycin DMSO inhibit treatment-induced increase
Akt1 (human) increase i Akt
augment treatment-induced decrease
rapamycin Akt1 (human) inhibit treatment-induced decrease
4-HT, SU6656 inhibit treatment-induced increase
Akt1 (human) increase inducible Akt1
4-HT Akt1 (human) no effect upon treatment-induced increase

S236-p - S6 (human)
Modsite: AKRRRLssLRAstsK SwissProt Entrez-Gene
Orthologous residues
S6 (human): S236‑p, S6 (mouse): S236‑p, S6 (rat): S236‑p, S6 (fruit fly): S235‑p, S6 (cow): S236‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Cellular systems studied:  cell lines
Species studied:  hamster
Comments:  RSV-transformed hamster fibroblasts H19, non transformed hamster fibroblasts NIL-2, NILA
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
DMSO increase
SU6656 DMSO inhibit treatment-induced increase
DMSO increase
SU6656 DMSO inhibit treatment-induced decrease
rapamycin DMSO inhibit treatment-induced increase
Akt1 (human) increase i Akt
augment treatment-induced decrease
rapamycin Akt1 (human) inhibit treatment-induced decrease
4-HT, SU6656 inhibit treatment-induced increase
Akt1 (human) increase inducible Akt1
4-HT Akt1 (human) no effect upon treatment-induced increase

Y419-p - Src (human)
Modsite: RLIEDNEytARQGAk SwissProt Entrez-Gene
Orthologous residues
Src (human): Y419‑p, Src iso2 (human): Y425‑p, Src (mouse): Y424‑p, Src iso2 (mouse): Y418‑p, Src (rat): Y419‑p, Src (chicken): Y416‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Cellular systems studied:  cell lines
Species studied:  hamster
Comments:  RSV-transformed hamster fibroblasts H19, non transformed hamster fibroblasts NIL-2, NILA
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
DMSO increase
SU6656 DMSO inhibit treatment-induced increase

T1462-p - TSC2 (human)
Modsite: GLRPRGytISDsAPs SwissProt Entrez-Gene
Orthologous residues
TSC2 (human): T1462‑p, TSC2 iso2 (human): T1419‑p, TSC2 iso3 (human): T1418‑p, TSC2 iso4 (human): T1439‑p, TSC2 (mouse): T1465‑p, TSC2 iso6 (mouse): T1443‑p, TSC2 (rat): T1466‑p, TSC2 iso2 (rat): T1423‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Cellular systems studied:  cell lines
Species studied:  hamster
Comments:  RSV-transformed hamster fibroblasts H19, non transformed hamster fibroblasts NIL-2, NILA
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
Akt1 (human) increase inducible Akt1
tamoxifen Akt1 (human) augment treatment-induced increase
Akt1 (human) no change compared to control
4-HT Akt1 (human) no change compared to control